Fig. 5: CML treatment effects determined using CML state-space disease states.

A Samples from the TOTO (left) and TKI (center) were projected into the CML state-space to allow the treatment effects to be compared to the CML disease states (right). B DEGs were identified by comparing the TOTO post-Rx and both the TKI Rx and post-Rx samples to the controls (Hs). All intersections with 10 or more DEGs are shown (all intersections shown in Fig. S7B). C After removing the age-related DEGs that were detected when comparing the early vs late control samples, the CML contribution of the 38 TOTO post-Rx vs controls DEGs were plotted and showed a small overall pro-CML contribution (black arrow). D The CML contribution of each of the TKI Rx vs control (Hs) DEGs were shown along with the overall CML contribution for all DEGs (black arrow). E Since the TKI Rx samples returned to a similar CML state-space ___location, the significantly enriched (adjusted p < 0.0001) GSEA Hallmark gene sets for the TKI Rx vs transition (Ts) DEGs were determined to identify what processes were affected by TKI treatment.